HCPLive 5 Stories in Under 5: Week of 10/12

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

Interested in a more traditional, text rundown? Check out the HCPFive!

Top 5 Healthcare Headlines for October 12-18, 2025:

1. FDA Accepts Inhaled Insulin (Afrezza) sBLA for Pediatric Diabetes

The FDA accepted MannKind’s sBLA for Afrezza inhaled insulin to expand its use to children and adolescents with type 1 or type 2 diabetes.

2. FDA Approves Updated Indication for Upadacitinib (Rinvoq) in IBD

The FDA broadened upadacitinib’s indication to allow use in ulcerative colitis and Crohn disease when tumor necrosis factor blockers are not clinically appropriate.

3. FDA Clears First Blood Test to Rule Out Alzheimer-Related Amyloid Pathology

The FDA cleared Elecsys pTau181 as the first blood test to help rule out Alzheimer-related amyloid pathology in older adults with cognitive symptoms.

4. Digital Therapeutic Reduces Negative Symptoms of Schizophrenia in Phase 3 Trial

A phase 3 study showed a prescription digital therapeutic significantly reduced negative symptoms in schizophrenia when used alongside antipsychotic therapy.

5. APPLAUSE-IgAN: Iptacopan (Fabhalta) Meets eGFR Decline Primary Endpoint

Iptacopan demonstrated meaningful efficacy in slowing kidney function decline in adults with IgA nephropathy, supporting future regulatory submissions.